As the biallelic loss of CDK12 is common in other types of tumours (133,134) and in some of them is associated with focal tandem duplications (96), the CDK12 aberrations have a potential to be used, next to MMR deficiency, as another biomarker of response to the therapy (94). The gene discussed is CDK12; the disease is neoplasm.